Q1 Earnings Forecast for GeoVax Labs Issued By Roth Capital

GeoVax Labs, Inc. (NASDAQ:GOVX) – Analysts at Roth Capital issued their Q1 2025 earnings estimates for shares of GeoVax Labs in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings of ($0.36) per share for the quarter. The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.18) EPS.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same period in the previous year, the business posted ($4.80) earnings per share.

A number of other equities research analysts have also recently issued reports on the company. Noble Financial boosted their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research report on Friday. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.25.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $2.43 on Thursday. The business has a 50-day moving average of $2.37 and a 200-day moving average of $2.60. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.